To estimate the accuracy of a new assay to determine the fetal RHD status using circulating cell-free DNA.
OBJECTIVE:
To estimate the accuracy of a new assay to determine the fetal RHD status using circulating cell-free DNA.
METHODS: This was a prospective, observational study. Maternal blood samples were collected in each trimester of pregnancy in 520 nonalloimmunized RhD-negative patients. Plasma samples were analyzed for circulating cell-free DNA using the SensiGENE RHD test, which used primers for exons 4 and 7 as previously described and incorporated a new primer design for exon 5 of the RHD gene. Neonatal serology for RhD typing using cord blood at birth was undertaken and results were stored in a separate clinical database. After unblinding the data, results of the DNA analysis were compared with the neonatal serology.
RESULTS:
Inconclusive results secondary to the presence of the RHD pseudogene or an RHD variant were noted in 5.6%, 5.7%, and 6.1% of the first-, second-, and third-trimester samples, respectively. The incidence of false-positive rates for RhD (an RhD-negative fetus with an RHD-positive result) was 1.54% (95% confidence interval [CI] 0.42-5.44%), 1.53% (CI 0.42-5.40%), and 0.82% (CI 0.04-4.50%), respectively. There was only one false-negative diagnosis (an RhD-positive fetus with an RHD-negative result), which occurred in the first trimester (0.32%; 95% CI 0.08-1.78%). Genotyping for mismatches across repeated samples revealed that this error was related to mislabeling of samples from two patients collected on the same day at one of the collection sites. Overall test results were in agreement across all three trimesters (P..99).
S
ince the widespread use of postpartum Rh immune globulin (RhIG) began in the late 1960s and since the routine administration of antenatal RhIG in the mid-1980s, the incidence of Rh alloimmunization has declined significantly in North America. In 1993, Lo et al 1 reported the successful use of circulating cell-free DNA in maternal plasma to accurately predict the fetal RhD status. A recent meta-analysis of 37 publications involving more than 11,000 samples found a positive predictive value of 95% with a negative predictive value of 98% for accurately determining fetal RhD. 2 Only one study performed in a U.S. laboratory using stored samples from a British population was included in this analysis. 3 Circulating cell-free DNA for RHD is now routinely used in many countries including the United States in the management of the alloimmunized pregnancy. 4 Based on Mendelian genetics, 38% of RhD-negative pregnant women will carry an RhD-negative fetus. In these cases, antenatal RhIG is unnecessary. Ethical and clinical concerns have therefore been raised regarding the unnecessary exposure of these pregnant women to a plasma-based product. 5 Antenatal RhIG has not been routinely used in many European countries as a result of the limited availability of the product since fear of Creutzfeldt-Jakob disease has led to the United States becoming the sole plasma source for the RhIG. Denmark, the Netherlands, and parts of Sweden now use routine circulating cell-free DNA testing to determine the fetal RHD status to decide which pregnant patient is a candidate for antenatal RhIG. [5] [6] [7] The purpose of the current trial was to estimate the accuracy of an improved circulating cell-free DNA assay in a statistically powered prospective study. In addition, we sought to assess whether there was a particular trimester in pregnancy when this determination would be most accurate.
MATERIALS AND METHODS
We conducted a prospective, observational study. Five hundred twenty patients were enrolled in the protocol. Patients in our previous pilot study were not included in the current investigation. 8 Only RhD-negative pregnant women in the first trimester with no evidence of red cell alloimmunization by initial antibody screen were eligible to participate. Pregnancy dating was established by menstrual dates or transfer dates in the case of in vitro fertilization. All dating was confirmed by first-trimester ultrasonography.
Approval was obtained from the investigational review board of the coordinating center (Baylor College of Medicine; H21656) and the steering committee of the North American Fetal Therapy Network. In addition, the individual institutional review boards of the participating centers also approved the protocol. All patients signed written informed consent.
Participants underwent venipuncture (a total of three) at 11-13 6/7, 16-19 6/7, and 28-29 6/7 weeks of gestation. Blood was placed in 10-mL ethylenediaminetetraacetic acid tubes and shipped at ambient temperature by overnight express carrier to Sequenom Laboratories in San Diego, California. The blood samples were centrifuged at 31,600 g for 10 minutes and then stored within 72 hours of collection at 280°C in uniquely bar-coded 1-mL aliquots. As defined in the study protocol, samples received outside of the 72-hour window were not analyzed because stability beyond this time point had not been established. Four 1-mL aliquots from each blood draw were used for DNA extraction. DNA extraction was automated on the Microlab STAR liquid handler using magnetic bead-based separation. At delivery, RhD typing of the neonate was undertaken using standard serologic methods to determine the phenotype.
All clinical data were entered by the coordinators at the various sites into a customized web-based database (MedSciNet AB, Karolinska Institute, Stockholm, Sweden). Periodic sites visits were conducted by the study sponsor to ensure accuracy between the source documents and the clinical database. Laboratory results were reported to MedSci AB programmers who matched the clinical data with the laboratory results. At the conclusion of the study, the final data were released to the Principal Investigator (K.J.M.) and an independent statistician.
The SensiGENE Fetal RHD Genotyping test is currently the only available circulating cell-free DNA test in the United States to determine the fetal RHD status. Briefly, the matrix-assisted laser desorption/ ionization-time-of-flight mass spectrometry platform was used to detect the control and fetal genetic sequences. The assay interrogates alleles for exons 4, 5, and 7 of the RHD gene as well as probes for the 37-base pair insertion in exon 4 (RHD pseudogene). Interrogation of the control gene TGIF served as a control from extraction to detection. For RHD genotype determinations, if one or none of the three targets were detected, the sample was reported as RhD-negative.
If all three targets were detected, the sample was reported as RHD-positive. Detection of only two of the three targets was reported as inconclusive. Results were also considered inconclusive if an RHD gene variant precluded our ability to detect all three exons or if the RHD pseudogene was detected.
The quality metric of greater than 104 fetal copies was imposed for the acceptance of samples based on the limit of detection of the RHD assay. 3, 9 Samples found to contain less than 104 fetal copies were excluded from the final analysis as "quantity not sufficient."
All samples in this study were genotyped with the Sample ID test, which utilized 44 single nucleotide polymorphisms selected with 45-55% heterozygosity. 10 This allowed comparison of samples from the three trimesters to be genetically matched to confirm they were obtained from the same patient. The discriminatory power based on this panel was such that the probability of a random match occurring between any two unique samples was 1.8310 219 . Any mismatches occurring through mislabeling of samples from collection through processing were identified before unblinding the data.
The study was designed to obtain at least 125 RhD-negative and 125 RhD-positive fetal phenotypes. Assuming a 10% rate of RhD negativity and a 45% rate of heterozygosity in RhD-positive individuals, a sample size of 413 patients would yield 125 RhDnegative neonates. Assuming that the accuracy of the test is 98%, the 95% confidence interval (CI) for accuracy would be 96-99%, which is within an acceptable range. An increase in the sample size of 25% (to 520 patients) was calculated to allow for miscarriages, patients lost to follow-up, patients enrolled but later determined not to meet inclusion criteria, quantity not sufficient samples, and other factors leading to participant or sample exclusion.
The analysis we used to document the falsepositive and false-negative rate as well as the sensitivity, specificity, and accuracy of circulating cell-free DNA in the prediction of neonatal RhD phenotype at birth was by estimating the proportion of correct predictions using the lower limit of a one-sided 95% CI. Accuracy was defined as the sum of true-positives and true-negatives divided by the total number of samples. The McNemar test was used to determine the agreement of test results across the trimesters. A P value ,.05 was considered to be statistically significant.
RESULTS
Consecutive patients were enrolled between September 2009 and April 2011 (clinicaltrials.gov #NCT00871195) at 17 study sites in the United States and Canada. No adverse events were observed in the study population. In the first trimester, 15 samples were not tested as a result of improper labeling, receipt at the laboratory after the stability period, or inability of the sample to be located (Fig. 1 ). An additional 40 samples were excluded as a result of lack of confirmatory neonatal serology, patient ineligibility, or duplicate sampling. One of the samples from the first trimester was determined to be quantity not sufficient based on an insufficient number of DNA copies (this sample was also excluded based on not having confirmatory neonatal serology). No other samples in the study were excluded as a result of insufficient fetal copy number. The final study population therefore consisted of 467 patients. Neonatal serology revealed 312 RhDpositive singletons, 11 sets of RhD-positive twins, one set of RhD-positive triplets, 129 RhD-negative singletons, four sets of RhD-negative twins, one set of RhD-negative triplets, and one set of RhDnegative and -positive twins. Thus, the proposed prestudy sample size estimation of 413 was attained.
The mean6standard deviation maternal age was 31.065.19 years; the median gravidity was 2 (range 1-13). Self-declared ethnicity was 86.9% Caucasian or white, 11.2% African American or black, 13.1% Hispanic or Latina, 0.8% Asian, and 1.2% other. The median gestational age at which samples were obtained in the first trimester was 12.3 weeks (range 10.7-14.7 weeks). Second-trimester samples were not obtained or were excluded in nine participants cases from the first trimester (Fig. 2) . The median gestational age at which samples were obtained in the second trimester was 18.0 weeks (range 15.1-24.4 weeks). Third-trimester samples were not obtained or were excluded in an additional 33 participants that were obtained in the second trimester (Fig.  3) . The median gestational age at which samples were obtained in the third trimester was 28.7 weeks (range 26.0-32.4 weeks). Figures 1-3 depict the outcome and results of the samples drawn in each of the trimesters. Inconclusive results secondary to the presence of the RHD pseudogene or an RHD variant were noted in 5.6%, 5.7%, and 6.1% of the first-, second-, and third-trimester samples, respectively. The false-positive rates for RhD (an RhDnegative fetus with an RHD circulating cell-free DNApositive result) were 1.54% (95% CI 0.42-5.44%), 1.53% (CI 0.42-5.40%), and 0.82% (CI 0.04-4.50%), respectively. There was only one false-negative diagnosis (RhD-positive fetus with RHD-negative maternal circulating cell-free DNA result), which occurred in the first trimester (0.32%; 95% CI 0.08-1.78%). Genotyping for mismatches across repeated samples Unauthorized reproduction of this article is prohibited.
revealed that this one false-negative case in the first trimester was related to mislabeling of samples from two patients collected on the same day at one of the collection sites. When the samples were corrected for their identity based on the genotyping in the second and third trimesters, the one false-negative RHD result in the first trimester was found to be an error. Corrected for the mislabeling, the false-negative rate was 0.0% (95% CI 0.00-1.22%). The overall test results were in agreement across all three trimesters (P..99) ( Table 1) .
DISCUSSION
In the current investigation, circulating cell-free DNA was found to have a high degree of accuracy in determining fetal RhD status. This result was not affected by the trimester when the maternal sample was drawn. False-positive and inconclusive results from a circulating cell-free DNA assay would result in the unnecessary use of antenatal RhIG; however, there would be no risk of sensitization. One drawback to the routine use of circulating cell-free DNA to determine the need for antenatal RhIG would involve cases in which the fetus was mistakenly determined to be RhD-negative, and therefore RhIG was not given.
Such a false-negative result for circulating cell-free DNA would therefore result in a missed opportunity to prevent alloimmunization. This occurred only 0.32% of the time at the first-trimester blood sampling in our study. A recent study from the Netherlands noted that antenatal alloimmunization without RhIG occurred in only 0.31% (95% CI 0.21-0.41%) of cases. 11 Continued use of cord serology at birth would afford the opportunity to correct any infrequent circulating cell-free DNA error and would allow for the postpartum administration of RhIG at that time in pregnancy when alloimmunization is still most likely to occur.
Inconclusive results in the current study were mainly a result of the presence of the RHD pseudogene. The RHD pseudogene is a DNA variant of the RHD gene in which all of the exons of the usual RHD gene are present but a stop codon is also present that prevents translation into the RhD antigen. Patients homozygous or hemizygous for the pseudogene are RhD-seronegative, whereas heterozygous patients carrying one copy of a wild-type RHD gene and one pseudogene are seropositive. Fourteen of the 22 patients (63%) carrying the pseudogene were of African American ethnicity. This is not surprising in that previous studies have documented the presence of the Copyright ª by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc.
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RHD pseudogene in 24% of this ethnic population. 12 Our assay could not determine whether the mother or the fetus was the carrier of the RHD pseudogene; therefore, the results were reported as "inconclusive" with the annotation that the pseudogene was detected. In these 22 patients, two thirds of the neonates were found to be serologically RhD-positive indicating that their mothers were the source of the RHD pseudogene. Administration of RhIG therefore would be indicated in these patients. The other third of neonates (n57) were found to be serologically RhD-negative and therefore the fetus (and possibly the mother) was the source of the RHD pseudogene. In those cases, RhIG was unnecessary so treating all "inconclusive" results because RhD-positive would therefore appear to be an appropriate strategy. There were 15 sets of twins and two sets of triplets in this study. However, in only one of these cases was there discordance between the twins for RhD; in this case, the maternal sample was correctly reported at RHD-positive. Free DNA levels have been reported to be lower in twins as compared with singleton gestations. 13 This may be related to a dilutional effect from the known increase in maternal blood volume in such pregnancies. In addition, in a clinical scenario with a "vanishing" twin that was RhD-positive, a seemingly false-positive diagnosis could result for the remaining RhD-negative twin. 14 In this case, RhIG administration would be indicated although after the birth of the surviving twin, it would be determined that the antenatal administration of RhIG was unnecessary. The limited data presented in this study do not allow us to assess the accuracy of circulating cell-free DNA in determining the RhD status of each fetus in multiple pregnancies.
Implementation of a routine policy of noninvasive screening for all RhD-negative women in the United States with circulating cell-free DNA to determine the fetal RhD type has the potential to save more than 1.5 million doses of RhIG annually when it is routinely administered at 28 weeks of gestation. Additional doses of this blood product during other antenatal events such as bleeding from placenta previa or at the time of invasive procedures could also be averted. These cost savings must be offset against the cost of the assay. Two previously reported cost analyses have reported that such a policy would not be cost-neutral either in the United Kingdom or Quebec; a third report from Alberta suggested that it would be cost-effective in that Canadian Unauthorized reproduction of this article is prohibited.
providence. [15] [16] [17] Hawk et al 18 undertook a cost analysis and found that a circulating cell-free DNA approach would not involve additional costs to the U.S. health care system only if the assay was priced at $119 or the cost of RhIG rose to $825 circulating cell-free DNA. The strength of this study is the large number of patients who were recruited at 17 different clinical sites. One limitation is that the majority of the patients enrolled were Caucasian (87%), with 13% being African American and only a small number of patients representing other ethnic groups. Although the study population is representative of the incidence of RhD negativity in the U.S population, the small number of samples from non-Caucasians may limit the usefulness of the current circulating cell-free DNA assay to other populations. Another weakness of the current study is that the samples were not run prospectively, but rather were frozen and batched for analysis. Samples arriving at the laboratory outside of a 72-hour window were not evaluated because stability had not been analyzed beyond this timeframe. In a clinical situation, a 72-hour window may be narrow for the shipment of samples around the United States. Since the completion of this study, circulating cell-free DNA is now routinely collected in Unauthorized reproduction of this article is prohibited.
Streck BCT blood tubes, which contain a formaldehyde-free preservative that allows for stable DNA for up to 5 days. Use of these collection tubes could alleviate issues with delayed transport of specimens.
In conclusion, circulating cell-free DNA provides a means of accurately determining fetal RhD status. First-trimester assessment of fetal RhD status after 10 weeks of gestation may be a useful tool in deciding which RhD-negative pregnant woman should receive antenatal RhIG. Such a change in practice would avoid the unnecessary administration of a blood product to approximately 1.5 million U.S. women annually.
A cost analysis study should be undertaken with a sensitivity analysis to determine the cost of the circulating cell-free DNA RHD assay that would support cost-neutrality to the U.S. health care system.
